Clinical Trial Update: Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for reslizumab in eosinophilic granulomatosis with polyangiitis (EGPA) related asthma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Eosinophilic Granulomatosis with Polyangiitis

Drugs mentioned

• reslizumab (reslizumab)

Snippet

Sponsor: National Jewish Health | Conditions: Asthma | Phase 2 | Status: UNKNOWN